Fractyl reported positive six-month topline results from the REMAIN-1 pivotal cohort evaluating Revita, an endoscopic duodenal mucosal resurfacing procedure intended to preserve weight loss after GLP-1 discontinuation, meeting its co-primary endpoint at p=0.0023. The company is reallocating resources to Revita, cutting roughly 45% of staff and halting internal development of its Rejuva gene therapy program, with an FDA de novo submission targeted for late 2026. Weight regain after incretin withdrawal is one of the central unsolved problems in metabolic medicine, and a one-time procedural intervention would represent a structural rather than pharmacological answer.
Key Points
- Revita met six-month co-primary endpoint with high statistical significance
- Targets weight maintenance after GLP-1 discontinuation, not initial loss
- FDA de novo filing planned late 2026; Rejuva gene therapy discontinued
Longevity Analysis
Most patients regain the majority of lost weight within a year of stopping incretin therapy, which makes durability — not initial response — the meaningful metabolic endpoint. Resurfacing the duodenal lining alters how the gut signals satiety and insulin sensitivity upstream of the hormonal cascade, an attempt to correct the signaling environment rather than override it indefinitely with a drug. For clinicians, the relevant question remains whether a single procedural intervention can sustain metabolic regulation across years without the daily adherence burden that undermines pharmacological maintenance, and the 12-month readout expected in early 2027 will be the first real test of that premise.
Original published by LT Wire.